Sucampo Pharmaceuticals — Investor Presentation (November 2013)
26 slides from Sucampo Pharmaceuticals's investor presentation, Nov 13, 2013
Slide 1: Sucampo: The Science of Innovation
Cary Claiborne, Chief Financial Officer Silvia Taylor, SVP, IR, PR & Corporate Communications $ sucampo The Science of Innovation
Slide 2: Agenda
Agenda . Company Introduction & Value Proposition oe . Commercial-Stage Company a) AMITIZA® Update b) RESCULA® Update . Prostone Platform Technology Pipeline Update . Financials Review . Upcoming Milestones & Recent Events . Conclusion $ sucampo 2 The Science of Innovation
Slide 3: Forward-Looking Statements
Forward-Looking Statements duct potential, future pros The following factors, among other: new information, which Sucampo incorporates by reference. $ sucampo The Science of Innovation
Slide 4: Sucampo Value Proposition
Sucampo Value Proposition Global Biopharmaceutical“Gom Two FDA-Approved Drugs AMITIZA RESCULA (unoprostone isopropyl) in ophthalmics glaucoma or ocular hypertension Stable & Growing Revenue & Royalty Base Significant source of funding Profitable — Q3 YTD Global Partnerships Unique Proprietary Prosto
Slide 5: Continued AMITIZA YOY Growth
Continued AMITIZA YOY Growth pee reported sales to $204M through September on prescriptions up 5.6% Q3 YoY" OIC Opportunity = 40-80% fl ny ; 3.5% YoY increase in Olc? pioic i from 26.5% increase** in TRx for targets in pain management, rheumatology, surgery and anesthesiology specialists* Sucampo i
Slide 6: AMITIZA U.S. OIC Launch: Building on Strengths and Heritage
AMITIZAU.S. OIC Launch: Buiiding on Strengths and Heritage | >7M prescriptions over 7 years | 7 Build on Strenath i from label | Yin Long-Term Safety Build on Strength in Efficacy* AMITIZA Coverage 80.5% 85.3% IN Build on Strength =, in Managed Care Access Part D All Channels € SUCAMPO é The Science
Slide 7: Global AMITIZA Approvals and Regulatory Status
Global AMITIZA Approvals and-Regulato 1 used for ae years and IBS-C H Switzerland i CIC(2009) a oie anes) eee cabot us. : OIC (filed) i ete cic (2008) neous a IBS-C (2008) OIC Approved (April 2013) $ sucampo 7 The Science of Innovation
Slide 8: AMITIZA Global Snapshot
AMITIZA Global Snapsho Japan * Sucampo Japan ae up 58.2% to $5.2M Q3 v: Q2 g eiome Beenie. to lopline for first nine ae of 2013 June disease awareness pilot shown to be effective in Lea ae to sk physicians abi aM ITIZA4 Abbottto conduct targeted consumer awareness effort 2 week limitation removal ef
Slide 9: AMITIZA Intellectual Property
AMITIZA Intellectual Property— AMITIZA has a robust U.S. patent estate + 13 patents Latest patents expire in 2027 Paragraph IV certificati 2, 2013 di ANDA submitted t Notice letter alleges the 126 claim: is in AMITIZAS formulation patents Al 's mail lure, use or d d on January composition, method of
Slide 10: RESCULA U.S. Overview
RESCULA U.S. Overviev New RESCULA Commercial ee RESCULA grew ay current prescribers 75% reduction in RESCULA Selling & Marketing expenses anticipated in 2014 Movin fori cd and flexibility, lower cost o Me house sales force eliminated promotional tactics, Tan eel to reach non-prescribers Continued Po
Slide 11: Sucampo's Proprietary Prostone Platform Technology
Sucampo's Proprietary: Prostone -Platform Technology Prostones: Functional body + lon-channel activators is and tissue regeneration Clinical safety profile of prostones is well-tolerated, as demonstrated by the clinical safety record of AMITIZA and RESCUL. jal of prostones is broad y dy established
Slide 12: Prostone mechanisms of action
AMITIZA Fluid Secretion ] Smooth Muscle Relaxation | \ Barrier Repair and Mucosal | { Nerve Stabilization | { tection | Prevents Neuronal Cell Death J Anti-Inflammatory " Activity $ sucampo The Science of Innovation See Reference 8
Slide 13: AMITIZA Clinical Development & Life Cycle Management
AMITIZA Clinical Development & Life Cycle Management Initiated liquid formulation Unoprostone Isopropyl for Retinitis Pigmentosa Retinitis Pigmentosa(RP) October 201 os Rone sules prefer not to te + Takeda funding 100% of development costs + NDAiling planned after trial ends 1H 2014 Pediatric Consti
Slide 14: Sucampo Prostone Pipeline
Sucampo Prostone Pipeline lon Channel Aci aes Cobiprostone Ss for Lumbar al Ste: for Oral Mucosi Lumbar Spinal Stenosis (LSS) Oral Mucositis + Degenerative change in lumbar spine; unmet medical : need with limited treatment options globally began October 31 : i t f : litati 1 therapy and chemotherap
Slide 15: Clinical Focus
CLINICAL FOCUS LEAD COMPOUNDS PHASE2 PHASE3 *Co-developing with R-Tech Ueno, Ltd ONGOING SUCAMPO he Science of Innovation
Slide 16: Trading Symbol and Financial Snapshot
rading Symbol SCMP (NASDAQ) i} Corporate Headquarters Bethesda, MD le tock Price (11-11-13), 52-Week Range $6.37, $10.48 to $4.41 hares Outstanding (11-11-13) Volume lay average) llarket Capitalization (11-11-13) 42.5M (1 class of common stock) 14,754 $270.5M nterprise Value (11-11-13) $237.5M Total
Slide 17: Financial Guidance
Financial Guidance Full Year 2013 Net Income, excluding special items $3M to $5M EPS, excluding special items $0.07 to $0.12 2014 $ sucampo The Science of Innovation
Slide 18: Upcoming Milestones
AMITIZA (a) (o) Ss NS v Pipeline ostone (9 a ° ¥ Completed O In Progress Obtain approval of OIC sNDA: 4 $10M milestone payment upon commercial launch of OIC Pursue strategic alliances; new AMITIZA indications / territories Grow sales in Japan in 2013 Submit pp i and U.K. by 1Q 2013 Begin active mark
Slide 19: Upcoming Milestones and Recent Events
Q4 2013, Q4 for Pediatric Functional Constipation of pha: ral Mucositi To ie Bealls of phase 2a trial of Vi ion sh channel activator for Lumbar Spinal 4H 2014 | AMITIZA OIC i in Switzerland / U.K. | $ sucampo 19 The Science of Innovation
Slide 20: Conclusion
Conclusion Two FDA-Approved Drugs * AMITIZA « RESCULA (unoprostone isopropyl) in ophthalmics glaucoma or ocular hypertension Stable & Growing Revenue & Royalty Base * Significant source of funding « Profitable —- Q3 YTD * Global Partnerships Unique * Proprietary Prostone Technology ¢ Robust pipeline
Slide 21: Sucampo
$ sucampo 21 The Science of Innovation
Slide 22: Trading Symbol and Financial Snapshot
trading Symbol SCMP (NASDAQ) Corporate Headquarters stock Price (11-11-13), 52- k Range Bethesda, MD $6.37, ae 48 to $4.4 Shares Outstanding (11-11- 3) @ et G cies of ck) Daily Volume (90-day average} 114,754 Market Capitalization (11- 11-13) $270.5M Enterprise Value (11-11-13) $237.5M ebt i Cash &
Slide 23: Terms of Sucampo's AMITIZA Agreement
Terms of Sucampo’s AMITIZA Agreement: Takeda Agreement Takeda shall promote, market, and sell AMITIZA in U.S. and Canada + Sucampo’s ti '% of | net sales + Sucampo earned san in upfront and $140M in development milestone payments as of 09/30/13 + Sucampo received $113M in reimbursement for R&D expen
Slide 24: Orange Book-listed patents concerning lubiprostone
fype of Patent ‘Compostion of matter (druig substance) ‘Therapeuticuse (treating constipation) a imposition of matter (drug product) Therapeuticuse (treating O10) ‘Therapeuticuse (treating constipation) E 5 2014 6.414.018 2020 6,583,174 2020 6,982,283 2022 7,084,148 20a 7,417,067 2020 7.795312 2024
Slide 25: Type of Patent
‘Type of Patent ‘Composttion of matter (drug substance and drug product) Therapeuticuse (treating O10) ‘Therapeuticuse (treating constipation) ‘Composttion of matter (drug product) Unoprostone ‘PatenitNo._ 5 0675 pHa os Ge and Woes ea NaS es) 6.88836 euticus rain oclerypentensionand glaucoma) “Type
Slide 26: References
References Clearview Analysis 2008 Internal Research AMITIZA Physician ATU W112013 ‘Sucampo data on file Fs 4 5. 6. Fingertip Formulary (NOV 2013) A 8 9. jindraj I 2011. January; 17(1):35-47. $ sucampo The Science of Innovation
Sucampo Pharmaceuticals — Investor Presentation (November 2013) on 6ix